LTR Pharma (ASX:LTP) completed the data evaluation phase of its clinical study on SPONTAN, its intranasal formulation of erectile dysfunction medication vardenafil, according to a Monday filing with the Australian Securities Exchange.
The study found that SPONTAN nasal spray had a 470% faster absorption rate than oral tablets and was well-tolerated with no serious adverse events, the filing said.
LTR Pharma shares were down nearly 2% in midday trade Tuesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。